

Curriculum Vitae



Professor Dr med. **Andreas Schneeweiss**
born 06.12.1961
in Heidelberg
married, 3 children

Education and Scientific Vita

Since 2020	Member of the extended Board of Directors of the National Center for Tumor Diseases Heidelberg
Since 2018	Fellow of the German Cancer Research Center
Since 2008	Member of the Board of Directors of the German Society of Senology
Since 2006	Head of Division Gynecologic Oncology at the National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg
Since 2006	Professor at the University of Heidelberg
10/2001	European Certification on Medical Oncology of the European Society of Medical Oncology
1998 – 2005	Consultant Oncology Department of Gynecology and Obstetrics, University of Heidelberg
1997 – 1998	Consultant Hematology and Oncology Department of Hematology, Oncology and Rheumatology, University of Heidelberg
07/1997	Specialization in Hematology and Oncology
10/1995	Specialization in Internal Medicine
1989 – 1997	Fellowship at the Department of Hematology, Oncology, Rheumatology and Cardiology, University of Heidelberg
12/1989	Doctoral Degree at the University of Heidelberg

1988 – 1989	Military service
11/1987	Graduation to Medical Doctor at the University of Heidelberg
1983	Internship at the Johns Hopkins Hospital in Baltimore, USA
1981 – 1987	Medical Studies at the University of Heidelberg
1972 – 1981	Helmholtz-Gymnasium , Heidelberg

Memberships

American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
German Cancer Society
Working Group Medical Oncology of the German Cancer Society
Working Group Gynecological Oncology of the German Cancer Society
German Society of Senology
German Society of Obstetrics and Gynecology

Fields of Main Interest

Innovative systemic treatments of breast cancer and gynecological cancers (phase I-IV studies)

- **Targeted drugs**, eg.
 - Antibodies
 - Small molecules (MTK inhibitors, PARP inhibitors)
- **Immunotherapies**
- **Dose-dense** chemotherapies

Detection and evaluation of prognostic and predictive molecular markers at the genome, epigenome, transcriptome and protein level, eg.

- Genomic aberrations
- Single nucleotide polymorphisms (SNPs)
- Gen expression profiles
- miRNAs

Detection and evaluation of circulating and disseminated tumor cells

Publikationen 2015-2023 (Selection)

Wahida A, Buschhorn L, Fröhling S, Jost PJ, **Schneeweiss A**, Lichter P, Kurzrock R. The coming decade in precision oncology: six riddles. **Nat Rev Cancer**. 2023 Jan;23:43-54.

Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübke K, Loibl S; GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. **Eur J Cancer**. 2022 Jan;160:100-111.

Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hutter B, Ishaque N, Hirsch S, Geldon L, Stenzinger A, Springfield C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröhling S, Sinn HP, Jäger D, Thewes V, Zapotka M, Lichter P, **Schneeweiss A**. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. **JCO Precis Oncol**. 2021. doi: 10.1200/PO.20.00248. [Epub ahead of print].

Denkert C, Seither F, **Schneeweiss A**, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübke K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. **Lancet Oncol**. 2021. doi: 10.1016/S1470-2045(21)00301-6. [Epub ahead of print].

Conte P*, **Schneeweiss A***, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. **Cancer**. 2020. doi: 10.1002/cncr.32873. [Epub ahead of print]

*Shared first author

Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. **Cancers** 11(12). pii: E1987, 2019.

Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübke K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. **Eur J Cancer** 106:181-192, 2019.

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, **Schneeweiss A**. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. **Ann Oncol** 30(8):1279-1288, 2019.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. **Invest New Drugs** 36:848-859, 2018.

Fremd C, Jaeger D, **Schneeweiss A**. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. **Expert Rev Anticancer Ther** 23:1-14, 2018.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. **Eur J Cancer** 89:27-35, 2018.

Schmid P, Adams S, Rugo HS, **Schneeweiss A**, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. **N Engl J Med** 379:2108-2121, 2018

Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F, Al-Batran SE, **Schneeweiss A**. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. **J Clin Oncol** 33:2444-9, 2015.